CT Lung — Low-Dose Screening

Low-dose non-contrast chest CT for lung nodule detection, COPD assessment, and lung cancer screening. No referral required for self-pay patients. Estimated price: €120–160.

Low-dose CT of the chest (LDCT) is the current international standard for lung cancer screening in high-risk populations, recommended by the European Society for Medical Oncology (ESMO) and the U.S. Preventive Services Task Force for individuals aged 50–80 with a significant smoking history. The technique uses a substantially reduced radiation dose compared to standard diagnostic chest CT — typically 1–2 mSv versus 5–7 mSv — while retaining the sensitivity to detect ground-glass opacities and solid nodules down to 4–6 mm in diameter: the size range where early-stage lung cancer is most curable. The clinical rationale for lung cancer screening is compelling. Non-small cell lung cancer has a five-year survival rate exceeding 85% when diagnosed at Stage I (tumour confined to the lung, <3 cm) — a stage achievable through CT screening — compared to under 20% for Stage IV disease, where most lung cancers are currently diagnosed symptomatically. The National Lung Screening Trial demonstrated a 20% reduction in lung cancer mortality with annual LDCT versus standard chest X-ray in high-risk smokers. Beyond screening, LDCT is used for evaluation of ground-glass opacities and infiltrates found on standard chest X-ray, follow-up of previously detected lung nodules under structured surveillance protocols (Fleischner Society guidelines), assessment of COPD severity and emphysema distribution, pre-operative lung mapping before thoracic surgery, and characterisation of mediastinal anatomy including the thymus, great vessels, and lymph nodes. No intravenous contrast is required for the standard lung screening protocol. Patients lie supine on the CT table and are asked to hold their breath for approximately five seconds during acquisition. The total examination time is under ten minutes from entering the department. No dietary preparation is needed. Rehabilitační klinika Malvazinky serves patients through Group Mediterra's integrated network of Czech healthcare facilities operating under VAMED Austria Group's quality framework. The OnkoPrevent preventive programme offered by the clinic is specifically designed to address oncological risk, including pulmonary cancer screening. The clinic's internal medicine and cardiology specialists can interpret CT lung findings in the context of the patient's overall preventive health assessment and recommend follow-up action where indicated. Pricing for low-dose chest CT in Czech private imaging facilities typically falls between 3,000 and 4,000 CZK (approximately €120–160), making this one of the most cost-effective cancer screening tools available internationally. Patients seeking lung screening as part of a broader preventive health programme can combine LDCT with the clinic's KardioPrevent or KPP programmes for a coordinated assessment across multiple organ systems.